CN106459201A - 结合人和食蟹猴CD3ε的抗体 - Google Patents

结合人和食蟹猴CD3ε的抗体 Download PDF

Info

Publication number
CN106459201A
CN106459201A CN201580026998.5A CN201580026998A CN106459201A CN 106459201 A CN106459201 A CN 106459201A CN 201580026998 A CN201580026998 A CN 201580026998A CN 106459201 A CN106459201 A CN 106459201A
Authority
CN
China
Prior art keywords
human
antibody
cells
ser
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580026998.5A
Other languages
English (en)
Chinese (zh)
Inventor
G·蒂芬塔勒
E·默斯纳
V·利夫克
J·普拉策
S·奥夫纳
C·耶格
M·里特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN106459201A publication Critical patent/CN106459201A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580026998.5A 2014-05-28 2015-05-22 结合人和食蟹猴CD3ε的抗体 Pending CN106459201A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14170140 2014-05-28
EP14170140.9 2014-05-28
EP14180572 2014-08-11
EP14180572.1 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (1)

Publication Number Publication Date
CN106459201A true CN106459201A (zh) 2017-02-22

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580026998.5A Pending CN106459201A (zh) 2014-05-28 2015-05-22 结合人和食蟹猴CD3ε的抗体

Country Status (13)

Country Link
US (3) US20170233475A1 (OSRAM)
EP (2) EP3149041A1 (OSRAM)
JP (1) JP6738285B2 (OSRAM)
KR (1) KR20170003591A (OSRAM)
CN (1) CN106459201A (OSRAM)
AU (1) AU2015266077A1 (OSRAM)
BR (1) BR112016022819A2 (OSRAM)
CA (1) CA2942453A1 (OSRAM)
IL (1) IL247740A0 (OSRAM)
MX (1) MX2016015389A (OSRAM)
RU (1) RU2016151235A (OSRAM)
SG (1) SG11201609950YA (OSRAM)
WO (1) WO2015181098A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111417719A (zh) * 2017-11-30 2020-07-14 豪夫迈·罗氏有限公司 B细胞培养方法
WO2023273762A1 (zh) * 2021-06-30 2023-01-05 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102850929B1 (ko) 2015-12-09 2025-08-27 에프. 호프만-라 로슈 아게 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
AU2018276419A1 (en) 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
IL267567B2 (en) * 2016-12-22 2024-08-01 Daiichi Sankyo Co Ltd Anti-cd3 antibody for use in the treatment or prophylaxis of cancer, and molecules containing said antibody
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US11319371B2 (en) * 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
KR102324568B1 (ko) 2017-06-21 2021-11-10 길리애드 사이언시즈, 인코포레이티드 HIV gp120 및 CD3을 표적화하는 다중특이적 항체
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
CA3074130A1 (en) * 2017-09-21 2019-03-28 WuXi Biologics Ireland Limited Novel anti-cd3epsilon antibodies
CN120399075A (zh) 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
JP7530299B2 (ja) 2018-05-24 2024-08-07 ヤンセン バイオテツク,インコーポレーテツド 抗cd3抗体及びその使用
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
CR20220594A (es) * 2020-05-27 2023-01-17 Janssen Biotech Inc Proteins comprising cd3 antigen binding domains and uses thereof
CA3189473A1 (en) * 2020-09-24 2022-03-31 Andreas Bultmann Novel human antibodies binding to human cd3 epsilon
CN114656562B (zh) 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
WO2022204316A2 (en) * 2021-03-24 2022-09-29 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
TW202244059A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
US20230295310A1 (en) * 2022-03-20 2023-09-21 Abcellera Biologics Inc. CD3 T-Cell Engagers and Methods of Use
CN118922448A (zh) * 2022-03-22 2024-11-08 莫佛塞斯公司 Cd3特异性的去免疫抗体
EP4496631A1 (en) 2022-03-23 2025-01-29 F. Hoffmann-La Roche AG Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
TW202404637A (zh) 2022-04-13 2024-02-01 瑞士商赫孚孟拉羅股份公司 抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
WO2005118635A2 (en) * 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
NZ580746A (en) * 2007-04-03 2012-05-25 Micromet Ag Cross-species-specific bispecific binders
CN107903325B (zh) * 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
JP2017521998A (ja) * 2014-05-12 2017-08-10 ヌマブ アクチェンゲゼルシャフト 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111417719A (zh) * 2017-11-30 2020-07-14 豪夫迈·罗氏有限公司 B细胞培养方法
CN111417719B (zh) * 2017-11-30 2023-08-29 豪夫迈·罗氏有限公司 B细胞培养方法
WO2023273762A1 (zh) * 2021-06-30 2023-01-05 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用

Also Published As

Publication number Publication date
JP6738285B2 (ja) 2020-08-12
SG11201609950YA (en) 2016-12-29
RU2016151235A3 (OSRAM) 2019-01-18
MX2016015389A (es) 2017-04-13
US20200299385A1 (en) 2020-09-24
IL247740A0 (en) 2016-11-30
EP3763739A1 (en) 2021-01-13
CA2942453A1 (en) 2015-12-03
AU2015266077A1 (en) 2016-09-29
RU2016151235A (ru) 2018-06-28
US20200325224A1 (en) 2020-10-15
KR20170003591A (ko) 2017-01-09
JP2017516786A (ja) 2017-06-22
US20170233475A1 (en) 2017-08-17
WO2015181098A1 (en) 2015-12-03
EP3149041A1 (en) 2017-04-05
BR112016022819A2 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
US20230279109A1 (en) Anti-tim3 antibodies and methods of use
US20200299385A1 (en) Antibodies binding to human and cynomolgus cd3 epsilon
JP7592050B2 (ja) 抗hla-g抗体とその使用
US20250051456A1 (en) Anti-hla-g antibodies and methods of use thereof
CN108368173B (zh) 抗pd1抗体及使用方法
EP2747781B1 (en) Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
JP2019500853A (ja) 抗tpbg抗体と使用方法
HK1231092A1 (en) Antibodies binding to human and cynomolgus cd3 epsilon
HK40011622B (en) Anti-hla-g antibodies and use thereof
HK1259019B (zh) 抗pd1抗体及使用方法
HK1241906B (zh) 抗tim3抗体及使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231092

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20210730

AD01 Patent right deemed abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1231092

Country of ref document: HK